Salvage Therapy for Prostate Cancer : AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy
PURPOSE: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of a three-part series focusing on treatment delivery for non-metastatic biochemical recurrence (BCR) after primary radical prostatectomy (RP). Please refer to Part I for discussion of treatment decision-making and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis.
MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles.
RESULTS: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease.
CONCLUSIONS: Optimizing and personalizing the approach to salvage therapy remains an ongoing area of work in the field of genitourinary oncology and represents an area of research and clinical care that requires well-coordinated, multi-disciplinary efforts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:211 |
|---|---|
| Enthalten in: |
The Journal of urology - 211(2024), 4 vom: 02. Apr., Seite 518-525 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morgan, Todd M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BCR |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 04.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/JU.0000000000003891 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369111672 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369111672 | ||
| 003 | DE-627 | ||
| 005 | 20240405233657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JU.0000000000003891 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM369111672 | ||
| 035 | |a (NLM)38421243 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morgan, Todd M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Salvage Therapy for Prostate Cancer |b AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of a three-part series focusing on treatment delivery for non-metastatic biochemical recurrence (BCR) after primary radical prostatectomy (RP). Please refer to Part I for discussion of treatment decision-making and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis | ||
| 520 | |a MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles | ||
| 520 | |a RESULTS: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease | ||
| 520 | |a CONCLUSIONS: Optimizing and personalizing the approach to salvage therapy remains an ongoing area of work in the field of genitourinary oncology and represents an area of research and clinical care that requires well-coordinated, multi-disciplinary efforts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a BCR | |
| 650 | 4 | |a biochemical recurrence | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a radiation therapy | |
| 650 | 4 | |a radical prostatectomy | |
| 650 | 4 | |a salvage | |
| 650 | 4 | |a salvage therapy | |
| 650 | 4 | |a therapy | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 700 | 1 | |a Boorjian, Stephen A |e verfasserin |4 aut | |
| 700 | 1 | |a Buyyounouski, Mark K |e verfasserin |4 aut | |
| 700 | 1 | |a Chapin, Brian F |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, David Y T |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Heather H |e verfasserin |4 aut | |
| 700 | 1 | |a Chou, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Jacene, Heather A |e verfasserin |4 aut | |
| 700 | 1 | |a Kamran, Sophia C |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sennett K |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkby, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Luckenbaugh, Amy N |e verfasserin |4 aut | |
| 700 | 1 | |a Nathanson, Ben J |e verfasserin |4 aut | |
| 700 | 1 | |a Nyame, Yaw A |e verfasserin |4 aut | |
| 700 | 1 | |a Posadas, Edwin M |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Phuoc T |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ronald C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of urology |d 1945 |g 211(2024), 4 vom: 02. Apr., Seite 518-525 |w (DE-627)NLM000006890 |x 1527-3792 |7 nnns |
| 773 | 1 | 8 | |g volume:211 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:518-525 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/JU.0000000000003891 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 211 |j 2024 |e 4 |b 02 |c 04 |h 518-525 | ||